The Australian pharmacy and pharmaceutical sector continues to see important developments across medication access, professional recognition, patient safety, and vaccine innovation. Here’s a quick snapshot of the stories shaping the industry this week.
🧬 First mRNA Flu Vaccine Receives FDA Approval
Moderna’s mRNA influenza vaccine, mFLUSIVA, has received approval from the US Food and Drug Administration, becoming the first approved mRNA-based seasonal flu vaccine. The milestone marks another major step forward for mRNA technology beyond COVID-19 applications.
🛡️ Guild Welcomes Community Pharmacy Safety Boost
The Pharmacy Guild of Australia has welcomed new measures designed to strengthen safety and security across community pharmacies, reinforcing protections for both pharmacy teams and patients. The initiative reflects ongoing efforts to create safer healthcare environments while supporting frontline pharmacy services.
💉 Mounjaro Remains Open for PBS Discussions
Eli Lilly has indicated that discussions regarding a Pharmaceutical Benefits Scheme (PBS) listing for Mounjaro (tirzepatide) may continue, despite earlier setbacks in pricing negotiations. The development offers renewed hope for broader patient access to the diabetes and weight management therapy in Australia.
Learn more about the latest update
#PharmacyAustralia #HealthcareInnovation #PharmaceuticalNews
